Advancing Heart Muscle
Regeneration Technology
Discover our groundbreaking hydrogel technology designed to treat patients with myocardial infarction
Myocardial Infarction
Cardiovascular diseases (CVDs) are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, ischaemic heart disease (9.1 million deaths) and stroke (6.6 million deaths) representing 85% of all CVD deaths worldwide.
​
Myocardial infarction provokes massive loss of contractile functioning cardiomyocytes, and infarcted lesions are replaced by non-functioning fibrotic tissue. Following scar formation, if healing has not sufficiently restored the heart’s contractile function, the ventricle will continue to change its shape, wall thickness, and mechanical properties. These changes are called adverse ventricular remodeling which leads to systolic dysfunction.
OrigiNova Medical is leading the way in developing an advanced hydrogel (DelX) based on hyaluronic acid to repair heart muscle after a myocardial infarction. Our mission is to provide an innovative treatment solution for heart muscle recovery and improve patient outcomes.
-
Biodegradable and biocompatible hydrogel
-
Promote faster healing of injured tissue
-
Support cells in relevant processes including survival, proliferation, and differentiation.
-
Stimulating angiogenesis
-
Reducing inflammation
-
Reducing the ventricular wall stress
About us
OrigiNova Medical is dedicated to pioneering advanced hydrogel technology for treatment of heart muscle after myocardial infarction. Our mission is to revolutionize the treatment of heart disease, offering new hope to patients worldwide.
Our team of experts is committed to pushing the boundaries of biotechnology to develop cutting-edge solutions that address unmet needs. We are driven by a passion for making a meaningful impact on the lives of individuals affected by heart conditions.
Dr Pete Ayre PhD BE
Co_Founder, Director, CEO
Medical and Scientific Advisory Board
He has a three-decade tenure in the field of class 3 medical device development in CEO, CSO, COO and R&D management roles of small and large teams. His contributions to science and engineering are evidenced by numerous patents and publications.
He has significant expertise and experience in the development of class 2 and 3 implantable medical devices and worked in the OR with many leading clinicians. Previous experience at Cochlear, Ventracor, Saluda, Thorvascular and CardioBionic Pty Ltd.
Dr Leila Montazeri PhD BE
Co_founder, Director, CSO & COO
​
A biomedical scientist and innovator with more than 10 years of experience in tissue engineering and regenerative medicine.
She has authored over 30 peer-reviewed scientific articles and has gained experience conducting research and working in research institutes, universities, and biotech companies in Iran, EU countries, and Australia.
​
Medical and Scientific Advisory Board ( MSAB)
Prof. Chris Hayward
BMedSc, MD, FRACP, FCSANZ
Chief Medical Officer
Professor Hayward is a Heart Failure and Transplant Cardiologist at St Vincent’s Hospital, Sydney. He has over 20 years of experience in Heart failure Research and implantation.
Prof. Glenn Edwards
BVSc, MACVSc
Prof. Edwards is an experienced Veterinary surgeon; he has experience in surgical techniques and implantable devices designed for both veterinary and human clinical use, including pre-clinical VADs. He has published over 100 papers and chapters in textbooks in veterinary, biomaterial, and medical literature because of this work.
Business Advisory Board
Prof. Moss is the executive chair of Eaton Capital, previously DAI Capital. The individual also serves as a professorial Chair specializing in Impact Investment, Blended Finance, and ESG Investing, with a focus on the United Nations Sustainable Development Goals.